FGFR2 and cholangiocarcinoma: Churi et al19 found that FGFR genetic aberrations were associated with better prognosis in cholangiocarcinoma; they examined the mutation profile of cholangiocarcinoma and found that the median OS of FGFR2 rearrangement-positive patients was 38.8 months.